1
|
Araujo GR, Aglas L, Vaz ER, Machado Y, Huber S, Himly M, Duschl A, Goulart LR, Ferreira F. TGFβ1 mimetic peptide modulates immune response to grass pollen allergens in mice. Allergy 2020; 75:882-891. [PMID: 31750952 PMCID: PMC7217028 DOI: 10.1111/all.14108] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 09/22/2019] [Accepted: 09/29/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Transforming growth factor β1 (TGFβ1) is a cytokine that exerts immunosuppressive functions, as reflected by its ability to induce regulatory T (Treg) cell differentiation and inhibit Th1 and Th2 responses. Hence, peptides that mimic the active core domain of TGFβ1 may be promising candidates for modulation of the allergic response. This study aimed to investigate a synthetic TGFβ1 mimetic peptide (TGFβ1-mim) for its ability to modulate the immune response during allergic sensitization to grass pollen allergens. METHODS The in vitro action of TGFβ1-mim was evaluated in human lung epithelial cells, Jurkat cells, and rat basophilic leukemia cells. The in vivo action was evaluated in a murine model of Phl p 5 allergic sensitization. Additionally, the Th2 modulatory response was evaluated in IL-4 reporter mice. RESULTS In vitro, TGFβ1-mim downregulated TNF-α production, IL-8 gene expression, and cytokine secretion, upregulated IL-10 secretion, and inhibited Phl p 5-induced basophil degranulation. During Phl p 5 sensitization in mice, TGFβ1-mim downregulated IL-2, IL-4, IL-5, IL-13, and IFN-γ, upregulated IL-10, and induced Treg cell production. Furthermore, mice treated with TGFβ1-mim had lower levels of IgE, IgG1, IgG2a and higher levels of IgA antibodies than control mice. In a reporter mouse, the mimetic inhibited Th2 polarization. CONCLUSION The TGFβ1-mim efficiently modulated various important events that exacerbate the allergic microenvironment, including the production of main cytokines that promote Th1 and Th2 differentiation, and the induction of allergen-specific regulatory T cells, highlighting its potential use in therapeutic approaches to modulate the immune response toward environmental allergens.
Collapse
Affiliation(s)
| | - Lorenz Aglas
- Department of BiosciencesUniversity of SalzburgSalzburgAustria
| | - Emília R. Vaz
- Laboratory of NanobiotechnologyInstitute of BiotechnologyFederal University of UberlândiaUberlândiaBrazil
| | - Yoan Machado
- Department of BiosciencesUniversity of SalzburgSalzburgAustria
- Present address:
Department of Oral Biological and Medical SciencesUniversity of British ColumbiaVancouverBCCanada
| | - Sara Huber
- Department of BiosciencesUniversity of SalzburgSalzburgAustria
| | - Martin Himly
- Department of BiosciencesUniversity of SalzburgSalzburgAustria
| | - Albert Duschl
- Department of BiosciencesUniversity of SalzburgSalzburgAustria
| | - Luiz R. Goulart
- Laboratory of NanobiotechnologyInstitute of BiotechnologyFederal University of UberlândiaUberlândiaBrazil
| | - Fatima Ferreira
- Department of BiosciencesUniversity of SalzburgSalzburgAustria
| |
Collapse
|
2
|
Scheiblhofer S, Thalhamer J, Weiss R. DNA and mRNA vaccination against allergies. Pediatr Allergy Immunol 2018; 29:679-688. [PMID: 30063806 PMCID: PMC6283005 DOI: 10.1111/pai.12964] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 03/09/2018] [Accepted: 07/23/2018] [Indexed: 12/20/2022]
Abstract
Allergen-specific immunotherapy, which is performed by subcutaneous injection or sublingual application of allergen extracts, represents an effective treatment against type I allergic diseases. However, due to the long duration and adverse reactions, only a minority of patients decides to undergo this treatment. Alternatively, early prophylactic intervention in young children has been proposed to stop the increase in patient numbers. Plasmid DNA and mRNA vaccines encoding allergens have been shown to induce T helper 1 as well as T regulatory responses, which modulate or counteract allergic T helper 2-biased reactions. With regard to prophylactic immunization, additional safety measurements are required. In contrast to crude extracts, genetic vaccines provide the allergen at high purity. Moreover, by targeting the encoded allergen to subcellular compartments for degradation, release of native allergen can be avoided. Due to inherent safety features, mRNA vaccines could be the candidates of choice for preventive allergy immunizations. The subtle priming of T helper 1 immunity induced by this vaccine type closely resembles responses of non-allergic individuals and-by boosting via natural allergen exposure-could suffice for long-term protection from type I allergy.
Collapse
Affiliation(s)
| | - Josef Thalhamer
- Department of Biosciences, University of Salzburg, Salzburg, Austria
| | - Richard Weiss
- Department of Biosciences, University of Salzburg, Salzburg, Austria
| |
Collapse
|
3
|
Machado Y, Duinkerken S, Hoepflinger V, Mayr M, Korotchenko E, Kurtaj A, Pablos I, Steiner M, Stoecklinger A, Lübbers J, Schmid M, Ritter U, Scheiblhofer S, Ablinger M, Wally V, Hochmann S, Raninger AM, Strunk D, van Kooyk Y, Thalhamer J, Weiss R. Synergistic effects of dendritic cell targeting and laser-microporation on enhancing epicutaneous skin vaccination efficacy. J Control Release 2017; 266:87-99. [PMID: 28919557 DOI: 10.1016/j.jconrel.2017.09.020] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 09/13/2017] [Indexed: 02/06/2023]
Abstract
Due to its unique immunological properties, the skin is an attractive target tissue for allergen-specific immunotherapy. In our current work, we combined a dendritic cell targeting approach with epicutaneous immunization using an ablative fractional laser to generate defined micropores in the upper layers of the skin. By coupling the major birch pollen allergen Bet v 1 to mannan from S. cerevisiae via mild periodate oxidation we generated hypoallergenic Bet-mannan neoglycoconjugates, which efficiently targeted CD14+ dendritic cells and Langerhans cells in human skin explants. Mannan conjugation resulted in sustained release from the skin and retention in secondary lymphoid organs, whereas unconjugated antigen showed fast renal clearance. In a mouse model, Bet-mannan neoglycoconjugates applied via laser-microporated skin synergistically elicited potent humoral and cellular immune responses, superior to intradermal injection. The induced antibody responses displayed IgE-blocking capacity, highlighting the therapeutic potential of the approach. Moreover, application via micropores, but not by intradermal injection, resulted in a mixed TH1/TH17-biased immune response. Our data clearly show that applying mannan-neoglycoconjugates to an organ rich in dendritic cells using laser-microporation is superior to intradermal injection. Due to their low IgE binding capacity and biodegradability, mannan neoglycoconjugates therefore represent an attractive formulation for allergen-specific epicutaneous immunotherapy.
Collapse
Affiliation(s)
- Yoan Machado
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
| | - Sanne Duinkerken
- Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
| | | | - Melissa Mayr
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
| | | | - Almedina Kurtaj
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
| | - Isabel Pablos
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
| | - Markus Steiner
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
| | | | - Joyce Lübbers
- Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
| | | | - Uwe Ritter
- Department of Immunology, University of Regensburg, Regensburg, Germany
| | | | - Michael Ablinger
- Division of Experimental Dermatology, EB House Austria, Department of Dermatology, Paracelsus Medical University, Salzburg, Austria
| | - Verena Wally
- Division of Experimental Dermatology, EB House Austria, Department of Dermatology, Paracelsus Medical University, Salzburg, Austria
| | - Sarah Hochmann
- Institute of Experimental and Clinical Cell Therapy, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Austria
| | - Anna M Raninger
- Institute of Experimental and Clinical Cell Therapy, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Austria
| | - Dirk Strunk
- Institute of Experimental and Clinical Cell Therapy, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Austria
| | - Yvette van Kooyk
- Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
| | - Josef Thalhamer
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
| | - Richard Weiss
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria.
| |
Collapse
|